Antiviral Therapies in the Management of Chronic Hepatitis C: The Present and the Future Pre-Test

 
Thank you for your interest in Boston University School of Medicine's program, "Antiviral Therapies in the Management of Chronic Hepatitis C: The Present and the Future". To help gauge audience knowledge, we would appreciate if you could complete this short pre-test. (All responses will be kept confidential)

If you have any questions, please contact our office (617-638-4605 or 800-688-2475 or cme@bu.edu).
1. Name:
2. Please create a personal code in the format the first 3 letters of your last name, birth month and birth day. (XXX/MM/DD) For example Mr. Smith, birth date of February 14 would be smi0214.
3. Please enter your email address to have a chance to win a Kindle Fire! (Completion of the pre-test will give you one entry in the draw)
*
4. Please enter your degree/credentials (i.e. MD, RN, NP)
*
5. Which Hepatitis C conference location do you plan to attend?
*
6. In treatment-naïve HCV patients initiated on boceprevir as part of a triple therapy regimen, which step do you take when early response is seen?
*
7. A 51-year-old male former IV drug user with genotype 1 HCV, and a viral load of 2.4 million IU/ml, is started on triple therapy of PegIFN/ribavirin and telaprevir. When the patient returns in three weeks, what would be his most likely complaint in terms of side effects of this regimen?
*
8. In terms of emerging combination therapy, daclatasvir in combination with which of the following, with or without ribavirin, showed sustained viral response at 24 weeks in genotype 1a/1b HCV?
*
9. How confident would you be treating the following patient?
• 45-year-old male
• Genotype 1 HCV; viral load of 1.2 million IU/ml
• Labs:
− AST: 103
− ALT: 135
− ALP: 102
− T. bili: 1.1
− INR: 1.0
− ALB: 3.6
− WBC: 7.3
− HCT: 40.1
− PLT: 98
• Ultrasound: Coarse echotexture, lobular contour, no masses noted.
• Spleen: 13 cm
Not confident at allNot very confidentModerately confidentConfidentVery confident
*
10. A patient is on a triple therapy regimen of telaprevir + PegIFN/ribavirin. According to recommendations, you discontinue his telaprevir at 12 weeks. If the patient shows extended rapid viral response, how long would you continue him on PegIFN/ribavirin before discontinuing?
*
11. According to recommendations, which of the following HCV genotypes would most benefit from IFN and ribavirin treatment?
*
12. How confident are you at managing severe rash associated with telaprevir treatment?
Not confident at allNot very confidentModerately confidentConfidentVery confident
*
13. A 35-year-old male with genotype 1 HCV is started on therapy. Boceprevir is added after 4 weeks. At eight weeks viral load is detectable. How long would you continue boceprevir treatment?
*
14. In a patient taking telaprevir who presents with a mild localized rash with pruritis, which step do you currently take?
*
15. How would you rate your knowledge of emerging therapies for HCV management?
Very lowLowMediumHighVery high
*
16. In a patient who is taking sildenafil and needs to be started on telaprevir or boceprevir, how often do you discontinue sildenafil before initiating the HCV treatment?
NeverRarelySometimesUsuallyAlways
*
17. While effective in many groups, triple therapy tends to be least effective in which group?
*
18. Please rate your level of agreement with the following statement:
In a patient on telaprevir triple therapy who presents with a severe rash with vesicles and bullae, I discontinue telaprevir treatment (may or may not continue PegIFN/ribavirin)?
Strongly disagreeDisagreeNeutralAgreeStrongly agree
*
19. Compared to PegIFN/ribavirin therapy alone, triple therapy of boceprevir + PegIFN/ribavirin would be more likely associated with which adverse reaction?
*
20. In which situation would you discontinue telaprevir treatment (may or may not continue treatment with PegIFN/ribavirin)?
Thank you for your participation!
Powered by SurveyMonkey
Check out our sample surveys and create your own now!